Five Dalton Venture Portfolio Companies Honored in 2025 VENTURE50 Awards

The company was founded in June 2023, focusing on the research and development of rehabilitation and elderly care robots, with an aim to address the challenges faced by disabled individuals in health and wellness. In June 2023, it graduated from the Miracle Creation Camp's spring session and received investment; in September, it won the first prize in Jiaxing's "Pilot Cup" Entrepreneurship Competition and received nearly ten million in support funds; in October, it was selected for the "Miracle Point® Incubator Plus" by MicroPort; in December, it established an overseas subsidiary in Germany. In March 2024, it launched the Embodied Intelligence Technology (Jiaxing) production base. In September 2025, it was included in the "Silver Tech Partnership Program" and has completed five rounds of financing amounting to nearly 100 million yuan.

Founded in 2022, the company focuses on the research and industrial application of bio-enzymatic recycling technology for waste PET plastics. It is the world's first enterprise to receive GRS certification using bio-based recycling technology. The company has developed a highly efficient PET-degrading enzyme that breaks down PET waste into monomers (rPTA and rEG) under normal temperature and pressure. These monomers are then polymerized into rbPET, which is widely used in food packaging, textile fibers, engineering materials, and optical devices, achieving infinite recycling of waste plastics. Currently, the company has built the world’s first pilot production base with an annual capacity of 300 tons of rPTA, and a 5,000-ton production line is expected to be operational by 2026.

The company was founded in 2020, focusing on the development of innovative Class III active implantable products, and is committed to providing cost-effective "closed-loop" heart failure management solutions for heart failure patients worldwide. At this stage, the products under research cover the management of both acute and chronic heart failure patients, mainly including: ① For chronic heart failure patients, long-term implantable products that integrate "treatment + diagnosis"; ② For acute heart failure inpatients, short-term electrical circulatory support (Electrical Circulatory Support) used as a circulatory assistance product. All products under research by the company are self-developed and world-first, with more than a hundred domestic and foreign invention patents applied for cumulatively.

Founded in 2021, the company focuses on solving the pain point of frequent dosing with eye drop formulations by utilizing its core technology of biodegradable long-acting sustained-release for ocular applications. Its key platform technology, iSus®, enables drug delivery lasting from several days to months on the ocular surface and in the posterior segment of the eye, significantly improving patient compliance and treatment outcomes.

Deepwise is committed to providing artificial intelligence and Internet healthcare solutions to medical service institutions both in China and abroad through breakthrough AI technologies and self-developed core algorithms. Deepwise gathers professional talents from multiple fields such as artificial intelligence, Internet cloud computing, and medical imaging. The company's core team consists of experienced professionals in the medical field and doctors and senior researchers from well-known universities inside and outside China.